Share This Link

Heart rate of 90 beats per minute: A heart rate of 90 beats per minute is within normal adult limits and does not indicate magnesium toxicity. Magnesium sulfate typically causes mild vasodilation and may slightly lower blood pressure, but a heart rate of 90 is not concerning in this context. This finding does not warrant discontinuation of therapy.

Mild flushing and diaphoresis: Flushing and sweating are common, expected side effects of magnesium sulfate administration due to peripheral vasodilation. These manifestations are generally mild and self-limiting and do not indicate toxicity. Ongoing monitoring is appropriate, but discontinuation of therapy is not required based on these findings alone.

Increased urinary output to 200 mL/hr: Adequate urine output is essential for magnesium excretion, and increased output suggests that renal clearance of magnesium is functioning effectively. Toxicity is more likely when urine output falls below 30 mL/hr, as magnesium accumulates in the body. Therefore, this finding indicates appropriate renal function rather than a need to discontinue therapy.

When she does not desire future pregnancies: Even if a client does not desire future pregnancies, MMR vaccination timing is not based on reproductive intentions alone but on current pregnancy status. The vaccine is still contraindicated during pregnancy regardless of future pregnancy plans. Additionally, rubella immunity is important for general health and community protection, not solely future childbearing.

Prior to giving birth: Administering MMR during pregnancy is contraindicated because it is a live attenuated vaccine that carries a theoretical risk of fetal infection. Even in the third trimester, vaccination is avoided to prevent any potential harm to the fetus. The correct timing is after delivery, not before birth.

Two weeks before attempting pregnancy again: While vaccination before conception is appropriate, the timing is not limited to two weeks prior to future pregnancy attempts. The standard recommendation is to administer the MMR vaccine immediately postpartum, and then advise the client to avoid pregnancy for at least 4 weeks after vaccination. Waiting until just before trying to conceive may delay protection unnecessarily.

Recalculate the EDD using 32 days as the average cycle length: Adjusting the calculation based on an assumed cycle length without objective confirmation introduces estimation bias and may still result in an inaccurate due date. While cycle length can influence ovulation timing, individual variability makes this method unreliable for precise dating. Clinical guidelines prioritize ultrasound confirmation over manual recalculations when uncertainty exists.

Rely on Naegele's rule and schedule follow-up visits based on this due date: Continuing to rely solely on Naegele’s rule despite an atypical menstrual cycle increases the risk of inaccurate gestational dating. This may lead to inappropriate timing of prenatal screenings, misinterpretation of fetal growth patterns, and incorrect classification of preterm or post-term pregnancy. When LMP data is unreliable, additional diagnostic confirmation is necessary.

Suggest the client refer to online due date calculators: Online calculators may use standard assumptions similar to Naegele’s rule and do not account for clinical variability or atypical menstrual patterns. They are not considered reliable diagnostic tools in clinical practice and cannot replace medical evaluation. Relying on non-clinical tools may compromise accuracy in prenatal care planning.

"These tests are offered to everyone.": While it is true that many prenatal tests are offered universally, this response does not address the client’s concern about choice or autonomy. It may sound directive and fails to emphasize that participation is voluntary. Clients need clear information about their right to accept or decline testing, not just that it is routinely offered.

"Many clients want to know ahead of time if there are concerns.": This response provides general information about the purpose of testing but does not directly answer the client’s question about whether the tests are required. It may also shift focus away from informed consent and client autonomy. While supportive, it does not clearly address decision-making rights.

"Tell me your concerns about having these tests performed.": This is an open-ended therapeutic communication response that encourages discussion, but it does not directly answer the client’s question. Although useful for exploring feelings, the client specifically asked about whether the tests are required. This response delays providing essential information about choice and autonomy.

The clients must utilize the surrogacy method to achieve pregnancy.: Surrogacy is only one of several available reproductive options and is not a mandatory requirement for LGBTQIA individuals. Many clients may conceive using their own gametes, donor sperm or eggs, intrauterine insemination, or in vitro fertilization depending on their specific circumstances. Reproductive care should be individualized rather than based on assumptions tied to sexual orientation or identity.

Clients who are members of the LGBTQIA community can only choose adoption: This limits reproductive options without medical or ethical justification. While adoption is a valid and common path to parenthood, many LGBTQIA individuals can and do achieve biological parenthood through assisted reproductive technologies. Restricting options based on identity alone reflects misinformation and bias rather than clinical evidence.

Many clients who are members of the LGBTQIA community utilize assistive reproductive technology.: Although this statement is generally true, it is not the best answer because it is less precise and does not clearly affirm that ART is an available and appropriate option for achieving pregnancy. It describes usage patterns rather than directly addressing reproductive capability and options. NCLEX-style questions typically favor the most direct and accurate clinical statement.

“The blood transfusion will help correct cerebral hemorrhage.”: Packed red blood cell transfusion does not directly treat or reverse cerebral hemorrhage. While HELLP syndrome increases the risk of stroke or intracranial bleeding due to severe hypertension and thrombocytopenia, transfused red cells primarily restore oxygen-carrying capacity and blood volume. Management of cerebral hemorrhage requires blood pressure control, neurosurgical intervention if indicated, and correction of coagulopathy rather than PRBC transfusion alone.

“The blood transfusion will improve damage to your kidneys.”: Kidney injury in HELLP syndrome is related to endothelial dysfunction, vasospasm, and possible acute tubular necrosis from severe preeclampsia-related pathology. Packed red blood cell transfusion does not repair renal tissue damage or directly improve kidney function. Renal recovery depends on stabilization of blood pressure, resolution of the underlying condition, and supportive renal management.

“The blood transfusion will improve your liver's blood flow.”: Liver dysfunction in HELLP syndrome results from microvascular endothelial injury, fibrin deposition, and hepatic ischemia, which may lead to elevated liver enzymes or even hepatic rupture. A blood transfusion does not directly restore hepatic perfusion or reverse liver injury. Management of liver involvement focuses on stabilizing the patient and correcting the underlying systemic condition rather than improving liver blood flow with transfusion.

This test will screen for ABO incompatibility.: ABO incompatibility is not evaluated using maternal serum alpha-fetoprotein testing. Instead, it is assessed through maternal blood typing and antibody screening, often including the indirect Coombs test. MSAFP levels are unrelated to maternal-fetal blood group incompatibility and do not provide information about hemolytic disease of the newborn.

This test will screen for gestational diabetes.: Gestational diabetes is screened using a glucose challenge test or oral glucose tolerance test, typically performed between 24 and 28 weeks of gestation. MSAFP testing does not assess glucose metabolism or insulin resistance. Therefore, it is not used in the evaluation of gestational diabetes.

This test will screen for fetal maturity.: Fetal maturity is assessed using other diagnostic indicators such as amniocentesis findings (e.g., lecithin-sphingomyelin ratio) or clinical assessments of gestational age and fetal lung development. MSAFP levels do not provide information about organ maturity or readiness for extrauterine life. Thus, this option is not correct.

Method of birth: The method of birth refers to whether delivery is vaginal or cesarean, but it does not address the client’s emotional distress or concerns about the deviation from their birth plan. While delivery method is a clinical consideration, it is not the primary issue in this scenario. The concern here is maintaining communication and involvement in decision-making rather than selecting a specific delivery route.

Antenatal steroid administration: Antenatal corticosteroids are used to accelerate fetal lung maturity in preterm pregnancies, typically before 34 weeks or when preterm delivery is anticipated. At 35 weeks with severe preeclampsia requiring immediate induction, steroids may not be the primary focus and do not address the client’s emotional concerns. This intervention is not relevant to resolving dissatisfaction with changes to the birth plan.

Expectant management protocols: Expectant management involves delaying delivery to prolong pregnancy and improve fetal outcomes when it is safe to do so. In cases of preeclampsia with severe features that have worsened, expectant management is contraindicated due to the high risk of maternal and fetal complications. Therefore, this option is not appropriate given the urgent need for delivery.

The client has previously given birth to an Rh-negative infant.: If the client previously delivered an Rh-negative infant, there would be no Rh antigen exposure from that pregnancy. Rho(D) immune globulin is only indicated when there is potential exposure to Rh-positive fetal blood cells. Therefore, this history alone does not indicate the need for prophylaxis.

The client has expressed a desire to conceive again.: Future pregnancy plans do not determine the need for Rho(D) immune globulin. The medication is given based on current risk of Rh sensitization, not reproductive intentions. While preventing sensitization is important for future pregnancies, the immediate indication is Rh incompatibility exposure during the current event.

The client has had significant blood loss during the procedure.: The amount of blood loss is not the determining factor for administering Rho(D) immune globulin. The key concern is whether fetal Rh-positive red blood cells may have entered the maternal circulation, not the volume of maternal bleeding.